VRTX · Health Care · CIK 0000875320
Vertex Pharmaceuticals
1,665 institutional managers reported a position in Vertex Pharmaceuticals for the quarter ended 31-mar-2026. This page carries the register only: what Vertex Pharmaceuticals owns in other companies has not been researched, so an empty holdings section here would mean nothing.
Share price
VRTX
Who owns Vertex Pharmaceuticals
From institutional 13F filings for the quarter ended 31-mar-2026.
1,665 managers reported a position, together holding 232.1m shares. The 40 largest are listed.
What this page does not show
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
The holdings side, meaning the stakes Vertex Pharmaceuticalsitself holds in other companies, is not covered here. Those sit in a company's own 10-Q and 10-K rather than in any ownership form, and reading them is slow work. The researched companies have been done that way and carry both directions.